| D6.1 | Report on QA practices from WP with regards to experimental set-ups | M12 | 1; UCD |
| D6.2 | Report on QA practices from WP with regards to experimental validation | M24 | 1; UCD |
| D6.3 | Final report on QA practices from WP | M30 | 1; UCD |
| D6.4 | Report on nanoparticle uptake and intracellular localization | M30 | 1; UCD |
| D6.5 | Evaluation report on degradation and dissolution in living cells | M40 | 1; UCD |
| D6.6 | Report on systematic toxicity screening data of new nanomaterials | M36 | 12; RIVM |
| D6.7 | Report on simplified low cost screening tests that could be applicable to SME’s etc. | M42 | 12; RIVM |
| D6.8 | Report on integrative pathways that are triggered by unusual nanoparticle geometries | M45 | 13; VITO |
| D6.9 | Report on unforeseen disease phenomena arising from interaction of living cells and organisms with novel nanomaterials | M45 | 11; MNI |
